Design Therapeutics

$21.42 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Design Therapeutics

Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. The Company is focused on developing small-molecule therapeutic candidates, called gene targeted chimeras (GeneTACs), that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. The Company’s pipeline product candidates are Friedreich ataxia and Myotonic dystrophy (CTG). Friedreich ataxia (FA) is a monogenic, autosomal recessive progressive disease. Myotonic dystrophy (DM1) is a monogenic, autosomal dominant, progressive neuromuscular disease that affects skeletal muscle, heart, brain and other organs.

Stock Analysis

last close $21.93
1-mo return 53.4%
3-mo return 80.9%
avg daily vol. 118.3T
52-week high 22.2
52-week low 9.61
market cap. $1.2B
forward pe -
annual div. -
roe -11.1%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 68.5%

Subscribe now for daily local and international financial news